Erythromycin Tablet, Film Coated
NDC Package 71209-101-05
Package Information
Erythromycin tablets is a medication used to treat certain eye infections (such as conjunctivitis). This formulation utilizes a tablet, film coated delivery system. Marketed by Cadila Pharmaceuticals Limited, this product is identified by NDC 71209-101 and is authorized under FDA application ANDA213628.
Identification & Billing
- RxCUI: 197650 - erythromycin 500 MG Oral Tablet
- RxCUI: 598006 - erythromycin 250 MG Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 71209 - Cadila Pharmaceuticals Limited
- 71209-101 - Erythromycin
- 71209-101-05 - 100 TABLET, FILM COATED in 1 BOTTLE
- 71209-101 - Erythromycin
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (71209-101). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 71209-101-05 identifies a specific commercial package of 100 tablet, film coated in 1 bottle of Erythromycin, a human prescription drug labeled by Cadila Pharmaceuticals Limited. This tablet, film coated is formulated for oral use and contains erythromycin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cadila Pharmaceuticals Limited on October 06, 2021. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat certain eye infections (such as conjunctivitis). It is also used to prevent certain eye infections in newborns. It belongs to a class of drugs known as macrolide antibiotics. Erythromycin works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.
How is this Cadila Pharmaceuticals Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 71209010105. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.